A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Status:
Completed
Trial end date:
2020-03-26
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the
safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each
dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label
Extension Phase.